IMV Inc IMVIF

RE:RE:The pembro trial may be...

[qwerty22]

The other issue I have with IMV's data presentation is it's all evaluable patient. That is they remove a number of enrolled patients who progressed rapidly before doing the analysis. In dlbcl I think they enrolled 25 and are evaluating 19. In Ovarian it's something like 45%. Other trials do this but they don't end up with so many un-evaluable the ones I've seen have a few percent, that for me skews the results much more positively.

The Nivolumab trial that gets 36% ORR doesn't seem to exclude any non-evaluable patients.
 

qwerty22 wrote:

I think that trial data and second link is first-line treatment which is different to r/r and has generally better outcomes as well. That's not comparable.

The first link is the trial the analyst mentioned the ongoing pembro trial in pd-l1+ patients but I guess the data from that isn't public. If Merck have that data then the head-to-head with pembro+dpx is the best comparable.

 

Breakthorough wrote: https://www.clinicaltrials.gov/ct2/show/NCT03990961?term=Pembrolizumab&cond=DLBCL&draw=2&rank=1 Or this: "The overall and complete response rate was 90% and 77%. With 255 months of median follow-up, 2-year progression-free survival (PFS) is 83%. PD-L1 expression was associated with non-GCB subtype, and improved PFS and survival. Pembrolizumab can safely be added to R-CHOP, and is associated with a high CR rate and 2-year PFS." https://pubmed.ncbi.nlm.nih.gov/32030732/